α-cell SLC38A5 supports amino acid-induced α-cell proliferation and glucagon secretion - Summary - MDSpire

α-cell SLC38A5 supports amino acid-induced α-cell proliferation and glucagon secretion

  • By

  • Katelyn Sellick

  • Anna Marie R. Schornack

  • Tyler J. Rodgers

  • Fedora O. Ogodo

  • Mounika Aramandla

  • Jade E. Stanley

  • Walter Siv

  • Matthew Shou

  • Nitin C. Shankar

  • Soham S. Saraf

  • Diana E. Stanescu

  • E. Danielle Dean

  • June 15, 2026

  • 0 min

Share

Objective:

To examine the direct contribution of SLC38A5 to α-cell proliferation and nutrient-sensitive signaling.

Approach:
    Key Findings:
    • SLC38A5 gene expression is highly enriched in pancreatic α cells in both mice and humans.
    • α-cell-specific deletion of Slc38a5 significantly reduced amino acid-induced glucagon secretion and α-cell proliferation.
    • Phosphorylation of ribosomal protein S6 was unaffected by SLC38A5 deletion, indicating SLC38A5-independent nutrient-responsive signaling.
    Interpretation:

    Limitations:
    • The study primarily focuses on male and female mice without extensive exploration of potential sex-specific differences.
    • The effects of SLC38A5 deletion were assessed in a controlled experimental setting, which may not fully replicate in vivo conditions.
    Conclusion:

Original Source(s)

α-cell SLC38A5 supports amino acid-induced α-cell proliferation and glucagon secretion

  • by Katelyn Sellick, Anna Marie R. Schornack, Tyler J. Rodgers, Fedora O. Ogodo, Mounika Aramandla, Jade E. Stanley, Walter Siv, Matthew Shou, Nitin C. Shankar, Soham S. Saraf, Diana E. Stanescu, E. Danielle Dean

  • June 15, 2026

Related Content

Telehealth Usability, Engagement Patterns, and Technical Infrastructure in Managing Noncommunicable Diseases Among Health Care Professionals in Brazil, Ghana, Honduras, and the United Kingdom: Multinational Cross-Sectional Study

Combo Therapy May Improve HbA1c in Type 2 Diabetes

Oral orforglipron could be more effective in reducing hemoglobin A1c and body weight, with no increased risk of hypoglycemia in patients with inadequately controlled type 2 diabetes.

A multi-method study on GPs’ perspectives on Lipoprotein(a) as an actionable cardiovascular risk factor